Sera Prognostics
Sera Prognostics Reports Q1 Revenues of $38K as Preterm Birth Test Commercialization Progresses
The firm has been engaging with payors and insurance plan administrators following the release of results from its study on the use of the firm's PreTRM Test.
Sera Prognostics Plans Studies to Support US and EU Expansion; Firm’s Q4 Revenues Fall 41 Percent
Premium
The company raised $57.5 million in February through a public offering, and the proceeds will be used to support commercial expansion in the US and EU.
Sera Prognostics Prices $50M Stock Offering
The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Sera Prognostics, OraSure, Geneoscopy
Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.
Sera Prognostics Q3 Revenues Drop 31 Percent, Firm Begins Consumer-Initiated Preterm Birth Testing
The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.
Aug 1, 2024
360Dx Top 30 Jumps 11 Percent in July
Jun 4, 2024
360Dx Top 30 Rises 3 Percent in May
Mar 21, 2024
Mar 1, 2024
360Dx Top 30 Creeps up 1 Percent in February
Nov 9, 2021
Sera Prognostics Revenues, Net Loss Up in Q3
Jul 14, 2021
Sera Prognostics Goes Public With $75M IPO
Jun 16, 2021